Abbvie Inc. Common Stock (ABBV) 58.54 $ABBV
AmerisourceBergen: A Great Growth Story
Bill Gunderson - Seeking Alpha - 1 hr 50 mins ago
AmerisourceBergen (NYSE: ABC ) is a distributor of drugs and health supplies based in Chesterbrook, Pennsylvania. It runs 26 U.S. pharmaceutical distribution centers, 4 U.S. specialty distribution centers, and 2 Canadian distribution hubs, in order...
ABC: 113.67 (+0.18), JNJ: 100.60 (-0.95), WBA: 84.68 (-1.31), MCK: 226.20 (-2.94), MWIV: 190.00 (+0.10), GILD: 98.13 (-2.56), CAH: 90.27 (-0.53), ABBV: 58.54 (+0.30)
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT
ABBV: 58.54 (+0.30), INFI: 13.98 (-0.34)
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, AbbVie, Yahoo and Microsoft - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 8:30AM CDT
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, AbbVie, Yahoo and Microsoft
YHOO: 44.43 (-0.52), JNJ: 100.60 (-0.95), ABBV: 58.54 (+0.30), GOOGL: 554.70 (-6.44), MSFT: 40.65 (-0.31)
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cr7mzg/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" report to their offering. End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating End-Stage Kidney Disease (end-stage renal disease or ESRD). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in End-Stage Kidney Disease (end-stage renal disease or ESRD) Therapeutics Clinical Trials - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Pfizer Inc. - Sanofi - Shire Plc - Merck & Co., Inc. - Baxter International Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/cr...age_kidney
BAX: 68.50 (-0.26), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
The Single Worst Practice of the Drug Industry
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Mar 31, 6:07AM CDT
For millions of ordinary folks like you and me, generic drugs make needed prescription medicines affordable. Generics also reduce the dent in our collective pocketbooks come tax time by cutting billions of dollars annually from the costs of...
ABT: 46.33 (-0.75), MRK: 57.48 (-0.86), TEVA: 62.30 (-0.22), ABBV: 58.54 (+0.30)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone
ENDP: 89.70 (-1.83), ACT: 297.62 (-7.14), AUXL: 36.47 (-0.06), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), CBRX: 6.21 (+0.09), ATRS: 2.71 (+0.09)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.47 (-0.06), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), ABBV: 58.54 (+0.30), RIGL: 3.57 (+0.22), NVS: 98.61 (-2.70)
Renal Failure Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frs3p/renal_failure) has announced the addition of the "Renal Failure Global Clinical Trials Review, H1, 2015" report to their offering. Renal Failure Global Clinical Trials Review, H1, 2015 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Renal Failure Therapeutics Clinical Trials - Sanofi - Amgen Inc. - F. Hoffmann-La Roche Ltd. - Novartis AG - AbbVie Inc. - Pfizer Inc. - AstraZeneca PLC - Shire Plc - Abbott Laboratories - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/8f...al_failure
JNJ: 100.60 (-0.95), ABT: 46.33 (-0.75), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 5:09PM CDT
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the marketing authorization application of their multiple sclerosis (MS) candidate, Zinbryta.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), ABBV: 58.54 (+0.30), ALKS: 60.97 (-1.55)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.77 (+1.37), CTRX: 59.54 (-0.29), ESPR: 92.60 (+0.56), ACAD: 32.59 (-0.76), BMRN: 124.62 (-4.51), ICEL: 16.43 (+0.01), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
Biotech Merger Monday Doesn't Squash Biotech Bubble Debate
at The Street - Mon Mar 30, 9:43AM CDT
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
PCYC: 255.95 (-0.48), HZNP: 25.97 (+0.19), MYL: 59.35 (-0.65), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.43 (-0.52), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 98.13 (-2.56), ACHN: 9.86 (-0.38), MRK: 57.48 (-0.86), IBB: 343.43 (-7.89), ABBV: 58.54 (+0.30)
7 Top Science Fiction Projects That Could Make or Break Google, Amazon or Facebook
at The Street - Sat Mar 28, 7:35AM CDT
Self-driving cars, Internet access delivered via balloons and drones, and a project to cheat death are just some of the seemingly outlandish initiatives being pursued by Silicon Valley.
AMZN: 372.10 (-2.49), FB: 82.21 (-0.98), ABBV: 58.54 (+0.30), GOOG: 548.00 (-4.03), NVS: 98.61 (-2.70)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 422.24 (-9.38), ABBV: 58.54 (+0.30)
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA(TM) (Daclizumab High-Yield Process) for Treatment of MS
Business Wire - Fri Mar 27, 6:00AM CDT
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA(TM) (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).
BIIB: 422.24 (-9.38), ABBV: 58.54 (+0.30)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
70.87 (-0.27), UTX: 117.20 (-1.63), KRFT: 87.11 (-3.50), PAH: 25.66 (-0.49), INTC: 31.27 (-0.19), PVH: 106.56 (+1.20), VG: 4.91 (-0.02), DFS: 56.35 (-0.44), RYAAY: 66.77 (+0.77), PAYX: 49.61 (-0.40), SONC: 31.70 (-0.59), MWV: 49.87 (-0.65), COST: 151.49 (-0.88), ABBV: 58.54 (+0.30), MMP: 76.71 (-2.33), REGN: 451.48 (-8.30), CSCO: 27.52 (-0.13), URI: 91.16 (-0.70), ROVI: 18.21 (-0.63), AVP: 7.99 (+0.09), KR: 76.66 (-0.58), FB: 82.21 (-0.98), IP: 55.49 (+0.28), PFE: 34.79 (-0.21), DIS: 104.89 (-1.23), COP: 62.26 (-1.74), AMGN: 159.85 (-4.45), WFC: 54.40 (-0.37), DENN: 11.40 (-0.09), CELG: 115.28 (-4.74), WWAV: 44.34 (-0.30), ISIS: 63.67 (-1.14), FPRX: 22.85 (-0.91)
The 5 Top Big-Cap Leaders: Are Any In Buy Range?
at Investor's Business Daily - Wed Mar 25, 3:13PM CDT
When it comes to stocks, it's often size or speed. But, to quote "Trading Places," -- Can't we have both? IBD's Screen of the Day is Big Cap Leaders. It includes liquid, large-cap stocks with a strong record of earnings growth. Let's meet the top...
MNK: 126.65 (-3.48), ELX: 7.97 (unch), PCYC: 255.95 (-0.48), QRVO: 79.70 (-1.70), SWKS: 98.29 (-1.84), ABBV: 58.54 (+0.30), PANW: 146.08 (-2.53), AAPL: 124.43 (-1.94), AVGO: 126.98 (-3.57)
How Gilead And AbbVie Closed The HCV Door On Merck
Shock Exchange - at Seeking Alpha - Wed Mar 25, 2:29PM CDT
GILD: 98.13 (-2.56), MRK: 57.48 (-0.86), ABBV: 58.54 (+0.30)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 155.22 (-2.05), BIIB: 422.24 (-9.38), IHF: 133.06 (-1.07), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MRK: 57.48 (-0.86), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), PTH: 60.60 (-1.08), XHS: 124.42 (-0.51), SLXP: 172.81 (+0.16), ABBV: 58.54 (+0.30)
AmerisourceBergen: A Great Growth Story
Bill Gunderson - Seeking Alpha - 1 hr 50 mins ago
AmerisourceBergen (NYSE: ABC ) is a distributor of drugs and health supplies based in Chesterbrook, Pennsylvania. It runs 26 U.S. pharmaceutical distribution centers, 4 U.S. specialty distribution centers, and 2 Canadian distribution hubs, in order...
ABC: 113.67 (+0.18), JNJ: 100.60 (-0.95), WBA: 84.68 (-1.31), MCK: 226.20 (-2.94), MWIV: 190.00 (+0.10), GILD: 98.13 (-2.56), CAH: 90.27 (-0.53), ABBV: 58.54 (+0.30)
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 10:30AM CDT
ABBV: 58.54 (+0.30), INFI: 13.98 (-0.34)
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, AbbVie, Yahoo and Microsoft - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 8:30AM CDT
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, AbbVie, Yahoo and Microsoft
YHOO: 44.43 (-0.52), JNJ: 100.60 (-0.95), ABBV: 58.54 (+0.30), GOOGL: 554.70 (-6.44), MSFT: 40.65 (-0.31)
End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cr7mzg/endstage_kidney) has announced the addition of the "End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" report to their offering. End-Stage Kidney Disease (end-stage renal disease or ESRD) Global Clinical Trials Review, H1, 2015" provides data on the End-Stage Kidney Disease (end-stage renal disease or ESRD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on End-Stage Kidney Disease (end-stage renal disease or ESRD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating End-Stage Kidney Disease (end-stage renal disease or ESRD). Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in End-Stage Kidney Disease (end-stage renal disease or ESRD) Therapeutics Clinical Trials - Amgen Inc. - Novartis AG - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Pfizer Inc. - Sanofi - Shire Plc - Merck & Co., Inc. - Baxter International Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/cr...age_kidney
BAX: 68.50 (-0.26), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), MRK: 57.48 (-0.86), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
The Single Worst Practice of the Drug Industry
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Mar 31, 6:07AM CDT
For millions of ordinary folks like you and me, generic drugs make needed prescription medicines affordable. Generics also reduce the dent in our collective pocketbooks come tax time by cutting billions of dollars annually from the costs of...
ABT: 46.33 (-0.75), MRK: 57.48 (-0.86), TEVA: 62.30 (-0.22), ABBV: 58.54 (+0.30)
Testosterone Replacement Therapy (TRT) - Global Strategic Business Report 2015: Easy-to-use Formulations - A Major Boost to TRT Market
M2 - Tue Mar 31, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zhhxcs/testosterone) has announced the addition of the "Testosterone Replacement Therapy (TRT) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The Global and the US markets are analyzed by the following Product Segments: Topicals, Patches, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - AbbVie, Inc. (US) - Acrux Limited (Australia) - Actavis, Inc. (US) - Antares Pharma, Inc. (US) - Auxilium Pharmaceuticals, Inc. (US) - Bayer HealthCare Pharmaceuticals (Germany) - Columbia Laboratories, Inc. (US) - Eli Lilly and Company (US) - Endo Pharmaceuticals Inc. (US) - ProStrakan Group PLC. (UK) - Trimel Pharmaceutical Corporation (Canada) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS AND MARKET TRENDS 3. COMPETITION 4. AN OVERVIEW OF SELECT DRUGS ON THE MARKET 5. TESTOSTERONE DEFICIENCY AND TRT - AN OVERVIEW 6. PRODUCT LAUNCHES/APPROVALS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 35 (including Divisions/Subsidiaries - 36) - The United States (21) - Canada (3) - Japan (1) - Europe (
- - Germany (1) - - The United Kingdom (4) - - Rest of Europe (3) - Asia-Pacific (Excluding Japan) (3) For more information visit http://www.researchandmarkets.com/research/zh...stosterone ENDP: 89.70 (-1.83), ACT: 297.62 (-7.14), AUXL: 36.47 (-0.06), LLY: 72.65 (-1.22), ABBV: 58.54 (+0.30), CBRX: 6.21 (+0.09), ATRS: 2.71 (+0.09)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.47 (-0.06), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), ABBV: 58.54 (+0.30), RIGL: 3.57 (+0.22), NVS: 98.61 (-2.70)
Renal Failure Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 3:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frs3p/renal_failure) has announced the addition of the "Renal Failure Global Clinical Trials Review, H1, 2015" report to their offering. Renal Failure Global Clinical Trials Review, H1, 2015 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Renal Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Renal Failure Therapeutics Clinical Trials - Sanofi - Amgen Inc. - F. Hoffmann-La Roche Ltd. - Novartis AG - AbbVie Inc. - Pfizer Inc. - AstraZeneca PLC - Shire Plc - Abbott Laboratories - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/8f...al_failure
JNJ: 100.60 (-0.95), ABT: 46.33 (-0.75), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), AZN: 68.43 (-1.51), AMGN: 159.85 (-4.45), ABBV: 58.54 (+0.30), NVS: 98.61 (-2.70)
Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 5:09PM CDT
Biogen (BIIB) and AbbVie (ABBV) announced that the European Medicines Agency has validated the marketing authorization application of their multiple sclerosis (MS) candidate, Zinbryta.
BIIB: 422.24 (-9.38), CBM: 39.63 (+4.04), ABBV: 58.54 (+0.30), ALKS: 60.97 (-1.55)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.77 (+1.37), CTRX: 59.54 (-0.29), ESPR: 92.60 (+0.56), ACAD: 32.59 (-0.76), BMRN: 124.62 (-4.51), ICEL: 16.43 (+0.01), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
Biotech Merger Monday Doesn't Squash Biotech Bubble Debate
at The Street - Mon Mar 30, 9:43AM CDT
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
PCYC: 255.95 (-0.48), HZNP: 25.97 (+0.19), MYL: 59.35 (-0.65), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 422.24 (-9.38), GE: 24.81 (-0.31), PCYC: 255.95 (-0.48), MON: 112.54 (-0.84), FRPT: 19.43 (-0.62), HON: 104.31 (-0.60), KRFT: 87.11 (-3.50), INTC: 31.27 (-0.19), BWLD: 181.24 (-1.73), AIR: 30.70 (-0.76), KMX: 69.01 (-0.21), JACK: 95.92 (-1.12), YHOO: 44.43 (-0.52), SONC: 31.70 (-0.59), CMG: 650.54 (-4.82), ABBV: 58.54 (+0.30), REGN: 451.48 (-8.30), UNP: 108.31 (-1.78), DK: 39.75 (-0.16), YUM: 78.72 (-0.69), MU: 27.13 (+0.45), SWKS: 98.29 (-1.84), AMGN: 159.85 (-4.45), NXPI: 100.36 (-2.07), BA: 150.08 (-2.62), PLKI: 59.82 (-0.92), FRGI: 61.00 (-1.03), HAIN: 64.05 (-0.23), WWAV: 44.34 (-0.30), ZOES: 33.29 (+0.37), QRVO: 79.70 (-1.70), CBRL: 152.14 (-0.65), CNI: 66.87 (+0.64), NDLS: 17.44 (-0.10), MCD: 97.44 (-0.44), AVGO: 126.98 (-3.57)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 98.13 (-2.56), ACHN: 9.86 (-0.38), MRK: 57.48 (-0.86), IBB: 343.43 (-7.89), ABBV: 58.54 (+0.30)
7 Top Science Fiction Projects That Could Make or Break Google, Amazon or Facebook
at The Street - Sat Mar 28, 7:35AM CDT
Self-driving cars, Internet access delivered via balloons and drones, and a project to cheat death are just some of the seemingly outlandish initiatives being pursued by Silicon Valley.
AMZN: 372.10 (-2.49), FB: 82.21 (-0.98), ABBV: 58.54 (+0.30), GOOG: 548.00 (-4.03), NVS: 98.61 (-2.70)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 422.24 (-9.38), ABBV: 58.54 (+0.30)
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA(TM) (Daclizumab High-Yield Process) for Treatment of MS
Business Wire - Fri Mar 27, 6:00AM CDT
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA(TM) (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).
BIIB: 422.24 (-9.38), ABBV: 58.54 (+0.30)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
70.87 (-0.27), UTX: 117.20 (-1.63), KRFT: 87.11 (-3.50), PAH: 25.66 (-0.49), INTC: 31.27 (-0.19), PVH: 106.56 (+1.20), VG: 4.91 (-0.02), DFS: 56.35 (-0.44), RYAAY: 66.77 (+0.77), PAYX: 49.61 (-0.40), SONC: 31.70 (-0.59), MWV: 49.87 (-0.65), COST: 151.49 (-0.88), ABBV: 58.54 (+0.30), MMP: 76.71 (-2.33), REGN: 451.48 (-8.30), CSCO: 27.52 (-0.13), URI: 91.16 (-0.70), ROVI: 18.21 (-0.63), AVP: 7.99 (+0.09), KR: 76.66 (-0.58), FB: 82.21 (-0.98), IP: 55.49 (+0.28), PFE: 34.79 (-0.21), DIS: 104.89 (-1.23), COP: 62.26 (-1.74), AMGN: 159.85 (-4.45), WFC: 54.40 (-0.37), DENN: 11.40 (-0.09), CELG: 115.28 (-4.74), WWAV: 44.34 (-0.30), ISIS: 63.67 (-1.14), FPRX: 22.85 (-0.91) The 5 Top Big-Cap Leaders: Are Any In Buy Range?
at Investor's Business Daily - Wed Mar 25, 3:13PM CDT
When it comes to stocks, it's often size or speed. But, to quote "Trading Places," -- Can't we have both? IBD's Screen of the Day is Big Cap Leaders. It includes liquid, large-cap stocks with a strong record of earnings growth. Let's meet the top...
MNK: 126.65 (-3.48), ELX: 7.97 (unch), PCYC: 255.95 (-0.48), QRVO: 79.70 (-1.70), SWKS: 98.29 (-1.84), ABBV: 58.54 (+0.30), PANW: 146.08 (-2.53), AAPL: 124.43 (-1.94), AVGO: 126.98 (-3.57)
How Gilead And AbbVie Closed The HCV Door On Merck
Shock Exchange - at Seeking Alpha - Wed Mar 25, 2:29PM CDT
GILD: 98.13 (-2.56), MRK: 57.48 (-0.86), ABBV: 58.54 (+0.30)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 155.22 (-2.05), BIIB: 422.24 (-9.38), IHF: 133.06 (-1.07), ACT: 297.62 (-7.14), VRX: 198.62 (-2.76), MRK: 57.48 (-0.86), SHPG: 239.29 (-2.69), PFE: 34.79 (-0.21), PTH: 60.60 (-1.08), XHS: 124.42 (-0.51), SLXP: 172.81 (+0.16), ABBV: 58.54 (+0.30)
